

Facts About Acute Myeloid Leukemia (AML)

Introduction

Acute myeloid leukemia (AML) is an aggressive, highly complex hematological malignancy typically diagnosed in older adults. Patients with AML often have multiple comorbidities and may not be candidates for aggressive remission induction chemotherapy, the standard of care since the 1970s. In recent years, high-throughput genetic sequencing identifying causal mutations and a better understanding of the biology of the disease have resulted in a wave of newly approved targeted therapies. These discoveries and drug approvals have resulted in better options and better outcomes for patients, particularly those who may be unable to tolerate aggressive chemotherapy.

This publication will review the updated AML subtype classifications, detail newly approved therapies, summarize current treatment recommendations, and provide information about the LLS Beat AML® Master Trial, a collaborative clinical study testing novel targeted therapies with the goal of improving outcomes for newly diagnosed patients with AML.

Highlights

- AML is a genetically heterogeneous hematologic malignancy typically diagnosed in older adults, with a male predominance.
- AML is expected to account for more than 20,000 cancer cases and more than 11,000 deaths in the US in 2023.
- A multidisciplinary diagnostic approach, including both karyotype and mutation analysis, is critical to predict rates of remission, relapse, and overall survival, and to identify patients likely to benefit from targeted therapies.
- The updated classification of AML (WHO 5th Edition, 2022) separates subtypes according to whether they are defined by genetic abnormalities or defined by differentiation.
- European Leukemia Network (ELN) recommendations for AML diagnosis and management are widely recognized. The 2024 revision includes updates to ELN genetic risk classification, criteria for response, and treatment. ELN 2024 updates included genetic risk classification for adults receiving less-intensive therapy.
- Since 2017, better understanding of the molecular basis of AML has been leveraged to produce 12 newly approved therapies for AML: for the treatment of newly diagnosed patients, those with relapsed and refractory (r/r) disease, and those ineligible for aggressive induction chemotherapy.
- The latest National Comprehensive Cancer Network (NCCN) Practice Guidelines should be consulted on specific recommendations for diagnosis, risk stratification, and treatment options for patients with AML.
- Referral for consideration to a clinical trial is recommended for any all patients with newly diagnosed AML.
- The Beat AML® Master Trial sponsored by The Leukemia & Lymphoma Society is a novel, collaborative clinical study designed to facilitate the approval of new drugs and optimize the treatment for AML by developing individualized treatment approaches.

This publication is supported by Kura Oncology, Inc.

Background and Prevalence

AML is the most common acute leukemia in adults, with an estimated 20,380 diagnoses and 11,310 deaths in the US in 2023.¹ Although it can be diagnosed at younger ages, older adults comprise the majority of patients—the median age at diagnosis is 65 to 67 years, and 54% of patients are diagnosed at age 65 years and older.² From 2005 to 2012, the incidence of AML increased 4.4% per year, likely due to the aging population; from 2012–2019, incidence rates declined by 0.9 percent per year, though the trend was not significant.³ AML is more common in males by a ratio of approximately 3:1.²

AML results from genetic or epigenetic changes in hematopoietic precursor cells, resulting in a clone of myeloid precursor cells that proliferates, but can't differentiate. These immature myeloblasts expand in the bone marrow, peripheral blood, and other tissues, with a corresponding reduction in the production of normal red blood cells, platelets, and mature granulocytes.²

The great majority of AML cases arise without an apparent cause, but known and suspected risk factors for AML (other than advanced age and male gender) include those shown in **Table 1**.

Table 1. Risk factors for AML⁴

Risk Factor	Examples
Environmental exposures	Benzene, ionizing radiation, cigarette smoke
Antecedent hematologic disorders	Clonal cytopenias of undetermined significance (CCUS), myeloproliferative disorders, myelodysplastic syndromes (MDS)
Genetic syndromes	Bloom syndrome, ataxiapancytopenia syndrome, Diamond-Blackfan anemia, Fanconi anemia, MIRAGE syndrome, Noonan syndrome, Kostmann syndrome, Shwachman-Diamond syndrome, Down syndrome ⁴
Previous cancer therapy (therapy-related MDS/AML or t-AML*)	Alkylating agents, topoisomerase inhibitors and radiation therapy exposure ²

* May constitute 7% to 15% of patients with AML⁴

Multidisciplinary Diagnostic Approach

A person with AML usually presents with symptoms of bone marrow failure: abnormally low levels of platelets, neutrophils, and red blood cells, and the presence of circulating leukemic blasts with the resulting complications of fatigue, pallor, weakness, increased infections, and bleeding.

The diagnosis of AML has undergone updates with the most recent updates to WHO 2022 and ICC 2022. In some cases the diagnosis can be made based on the presence of $\geq 20\%$ myeloblasts in the marrow or peripheral blood established by morphology and flow cytometry, or by specific cytogenetic/molecular abnormalities.^{5,6} However, WHO 2022 now eliminates 20% blast requirement for diagnosis for all AML with defining genetic abnormalities with the exception of *BCR::ABL*. In comparison to WHO 2022, ICC 2022 requires blast cutoff of 10% for AML with recurrent genetic abnormalities. Both systems indicate that the requirement of 20% blasts for AML with *BCR::ABL1* fusion is to avoid overlap with chronic myeloid leukemia (CML).⁴⁴

The 2025 NCCN Practice Guidelines (www.NCCN.org) recommend a multidisciplinary diagnostic approach when AML is suspected. This approach identifies AML subtypes, stratifies pre-treatment risk and guides treatment decisions, and includes performing the following tests:²

- 1. Bone marrow core biopsy and aspirate analysis** (including immunophenotyping by flow cytometry and cytochemistry).
- 2. Cytogenetic analysis:** Karyotype with fluorescence in situ hybridization is needed for risk stratification and can potential guide therapy.
- 3. Mutational analysis:** Screening for *ASXL1*, *BCOR*, *CEBPA*, *DDX41*, *KIT*, *EZH2*, *FLT3*, *IDH1/2*, *NPM1*, *RUNX1*, *SF3B1*, *SRSF2*, *STAG2*, *TP53*, *U2AF1*, *BCR::ABL*, and *PML::RARA* should be performed in all patients to inform prognosis and treatment.

While identifying karyotype is critical to predict rates of remission, relapse and overall survival, mutation analysis refines risk stratification and identifies those patients likely to benefit from recently approved targeted therapies.⁸

Subtype Classification and Risk Stratification Critical for Treatment Decisions

Classification systems for AML have continued to evolve as new information on the disease is discovered. The WHO classification of AML and related neoplasms was previously based on clinically relevant disease information rather than only morphology.⁶ However, in the 5th edition (2022),⁹ the WHO reenvisioned AML classification, separating AML with genetic abnormalities from AML defined by differentiation, as shown in **Table 2**. In contrast to the WHO classification, the ICC classification 2022 updates have reenvisioned AML

classification based on a cut off of 10% blasts and genetic abnormalities, as shown in **Table 3**.⁴⁵

Recommendations from the ELN are widely used to establish genetic risk classification at diagnosis. The 2022 version of the ELN recommendations includes significant updates, including the removal of *FLT3*-ITD allelic ratio from risk classification (**Table 4**). The ELN has emphasized that its risk classification system is based on data from patients receiving intensive treatment.^{5,7} In 2024 ELN released a genetic risk classification framework for patient with newly diagnosed AML receiving less-intensive therapy (**Table 5**). The 2024 ELN Less-Intensive genetic risk classification is applicable to patients receiving HMA monotherapy, HMA/VEN, or AZA/IVO (for IDH1mut AML).⁴⁶

Table 2. AML and Related Neoplasms⁹

AML with Defining Genetic Abnormalities
• Acute promyelocytic leukemia with PML::RARA fusion
• AML with RUNX1::RUNX1T1 fusion
• AML with CBFB::MYH11 fusion
• AML with DEK::NUP214 fusion
• AML with RBM15::MRTFA fusion
• AML with BCR::ABL1 fusion
• AML with KMT2A rearrangement
• AML with MECOM rearrangement
• AML with NUP98 rearrangement
• AML with NPM1 mutation
• AML with CEBPA mutation
• AML, myelodysplasia-related
• AML with other defined genetic alterations
AML Defined by Differentiation
• AML with minimal differentiation
• AML without maturation
• AML with maturation
• Acute basophilic leukemia
• Acute myelomonocytic leukemia
• Acute monocytic leukemia
• Acute erythroid leukemia
• Acute megakaryoblastic leukemia

Table 3. AML with Recurrent Genetic Abnormalities (10% blast threshold)⁴⁵

• RUNX::RUNX1T1
• CBFB::MYH11
• DEK::NUP214
• KMT2A rearrangement
• MECOM rearrangement
• Other rare recurring translocations
• NPM1 mutations
• In-frame bZIP CEBPA mutation
• BCR::ABL* (Must have >20% blast for AML diagnosis)

Table 4. Risk Stratification by Genetics^{5,7}

Risk Category	Genetic Abnormality
Favorable	<ul style="list-style-type: none"> • t(8;21)(q22;q22.1) / <i>RUNX1-RUNX1T1</i> • inv(16)(p13.1q22) or t(16;16)(p13.1;q22) / <i>CBFB-MYH11</i> • Mutated <i>NPM1</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD • bZIP in-frame mutated CEBPA
Intermediate	<ul style="list-style-type: none"> • Mutated <i>NPM1</i> with <i>FLT3</i>-ITD • Wild-type <i>NPM1</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD (without adverse-risk genetic lesions) • t(9;11)(p21.3;q23.3) / <i>MLL3-KMT2A</i> • Cytogenetic and/or molecular abnormalities not classified as favorable or adverse
Adverse	<ul style="list-style-type: none"> • t(6;9)(p23;q34.1) / <i>DEK-NUP214</i> • t(v;11q23.3) / <i>KMT2A</i> rearranged • t(9;22)(q34.1;q11.2) / <i>BCR-ABL1</i> • t(8;16)(p11.2;p13.3) / <i>KAT6A-CREBBP</i> • inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) / <i>GATA2, MECOM(EVI1)</i> • -5 or del(5q); -7; -17/abn(17p) • Complex karyotype, monosomal karyotype • Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 • Mutated <i>TP53</i>

Table 5. ELN Risk Classification for Patients Receiving Less-intensive Therapies (ELN 2024 Less-Intensive)⁴⁶

Risk Category	Genetic Abnormality
Favorable	<ul style="list-style-type: none"> • Mutated <i>NPM1</i> (<i>FLT3</i>-ITDneg, <i>NRAS</i> wt, <i>KRAS</i> wt, <i>TP53</i>wt) • Mutated <i>IDH2</i> (<i>FLT3</i>-ITDneg, <i>NRAS</i> wt, <i>KRAS</i> wt, <i>TP53</i>wt) • Mutated <i>IDH1</i> (<i>TP53</i>wt) • Mutated <i>DDX41</i> • Other cytogenetic and/or molecular abnormalities[†] (<i>FLT3</i>-ITDneg, <i>NRAS</i> wt, <i>KRAS</i> wt, <i>TP53</i>wt)
Intermediate	<ul style="list-style-type: none"> • Other cytogenetic and molecular abnormalities (<i>FLT3</i>-ITDpos and/or <i>NRAS</i> mut and/or <i>KRAS</i> Mut; <i>TP53</i>wt)
Adverse	<ul style="list-style-type: none"> • Mutated <i>TP53</i>

Treatment and Prognosis

Despite the genetic heterogeneity of AML, for decades most patients who were fit enough (generally younger patients) received aggressive induction combination chemotherapy consisting of 7 days of cytarabine and 3 days of anthracycline (“7 + 3” regimen), followed by either cytarabine-based consolidation or allogeneic hematopoietic stem cell transplant (HSCT).¹⁰ This regimen results in complete remission in approximately 70% of patients younger than 60 years, and approximately 50% of those 60 years and older.⁸

Relapse occurs frequently, however, ranging from 30%–35% in younger patients with favorable risk factors to 70%–80% in older patients with adverse risk factors. In 2017, the overall survival (OS) rate at 5 years for patients with AML was 27.4%. Adjusted for age, 5-year OS for those younger than 65 was 39% and just 8.5% for patients 65 to 74 years of age.¹¹ Even with active therapy, the typical median OS in r/r AML is approximately 6 months.¹²

Options for patients with AML who are ineligible for aggressive chemotherapy have been limited. Less-intensive treatment approaches have included low dose cytarabine (LDAC), which is associated with poor response rates (<15%) and short median survival.^{13,14} Hypomethylating agents have also been utilized in these patients, resulting in complete response (CR) plus CR with incomplete blood count recovery (CRi) of 20–40%.^{13,14} Other such patients receive no chemotherapy but opt for supportive care, including hydroxyurea and transfusion support, instead.^{13,14}

Therapies Approved Since 2017

Recently, better understanding of the molecular basis of AML has been leveraged to produce 12 approved therapies from 2017 to 2022—either as single agents or in combination with other therapies (**Table 6**). These approvals have provided welcome treatment options for patients with AML, particularly older patients. A brief description of each is found below. Updated 2023 NCCN Practice Guidelines, available at www.jnccn.org/view/journals/jnccn/17/6/article-p721.xml, should be consulted for detailed recommendations regarding where and when each of these therapies fits into clinical practice for the treatment of patients with AML.² The full Prescribing Information for each of these therapies should be consulted to learn about associated toxicities.

Table 6. Therapies for AML Approved Since 2017

Therapy	Mechanism of Action	Indication(s)
Daunorubicin and cytarabine liposome (VYXEOS®) ¹⁵ [Approved 2017]	Fixed molar ratio of daunorubicin and cytarabine in a liposomal formulation	<ul style="list-style-type: none"> Adults with newly diagnosed therapy-related AML (t-AML) AML with myelodysplasia-related changes (AML-MRC)
Gemtuzumab ozogamicin (MYLOTARG™) ¹⁶ [Approved 2017]	Anti-CD-33 antibody linked to N-acetyl gamma calicheamicin, a cytotoxic agent	<ul style="list-style-type: none"> Adults with newly diagnosed CD33-positive AML either as single agent or in combination with 7+3 Relapsed/refractory (r/r) CD33-positive AML in patients >2 years
Midostaurin (RYDAPT®) ¹⁷ capsules [Approved 2017]	FMS-like tyrosine kinase 3 (FLT3) inhibitor	<ul style="list-style-type: none"> In combination with standard cytarabine and daunorubicin induction and cytarabine consolidation in adults with newly diagnosed AML that is <i>FLT3</i>-ITD or <i>FLT3</i>-TKD
Gilteritinib (XOSPATA®) ¹⁸ oral tablets [Approved 2018]	FMS-like tyrosine kinase 3 (FLT3) inhibitor	<ul style="list-style-type: none"> Adults with r/r AML with <i>FLT3</i>-ITD or <i>FLT3</i>-TKD mutations detected by an FDA-approved test.
Enasidenib (IDHIFA®) ¹⁹ oral tablets [Approved 2017]	IDH2 inhibitor	<ul style="list-style-type: none"> Adults with r/r AML with <i>IDH2</i> mutation
Ivosidenib (TIBSOVO®) ²⁰ oral tablets [Approved 2018]	IDH1 inhibitor	For treatment of AML with a susceptible <i>IDH1</i> mutation in: <ul style="list-style-type: none"> As monotherapy or with azacitidine in adults with newly diagnosed AML, who are ≥75 years or have comorbidities precluding intensive induction chemotherapy As monotherapy in adults with r/r AML
Venetoclax (VENCLEXTA®) ²⁰ tablets [Approved 2018]	BCL-2 inhibitor	<ul style="list-style-type: none"> With hypomethylating agents (azacitidine or decitabine) or low dose cytarabine (LDAC) for treatment of newly diagnosed AML in adults ≥75 years or who have comorbidities that preclude use of intensive induction chemotherapy
Glasdegib (DAURISMO™) ²² oral tablets [Approved 2018]	Hedgehog pathway inhibitor	<ul style="list-style-type: none"> With LDAC for treatment of newly diagnosed AML in adults ≥75 years or who have comorbidities that preclude use of intensive induction chemotherapy
Azacitidine (ONUREG™) ²³ oral tablets [Approved 2020]	Nucleoside metabolic inhibitor	<ul style="list-style-type: none"> Continued treatment of adults with AML in first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy (and are unable to complete intensive therapy)
Olutasidenib (REZLIDHIA™) ²⁴ oral capsules [Approved 2022]	IDH1 inhibitor	<ul style="list-style-type: none"> Adults with r/r AML with a susceptible <i>IDH1</i> mutation
Revumenib (REVUFORJ®) ⁵² oral tablets [Approved 2024]	Menin inhibitor	<ul style="list-style-type: none"> Adult and pediatric patients age >1 year with R/R KMT2A-rearranged with AML
Quizartinib (VANFLYTA®) ⁵³ oral tablets [Approved 2023]	FMS-like tyrosine kinase 3 (FLT3) inhibitor	<ul style="list-style-type: none"> In combination with standard cytarabine and daunorubicin induction, cytarabine consolidation and single agent maintenance in adults with newly diagnosed AML that is <i>FLT3</i>-ITD positive

Daunorubicin and cytarabine liposome (VYXEOS®) for injection [approved in 2017]

The “7 + 3” regimen of cytarabine and daunorubicin has been used for the treatment of AML for over 40 years. Studies have demonstrated that cytarabine and daunorubicin are maximally effective against malignant cells when 5 times as much cytarabine as daunorubicin is present, however, separate infusion of these agents does not serve to maintain this 5:1 molar ratio.²⁵

The recently approved liposome formulation maintains a 5:1 molar ratio of cytarabine/daunorubicin within the liposome after injection, stabilizes both drugs and preferentially targets leukemic cells.²⁵ In clinical studies in older adults (ages 60–75 years) with AML, OS was significantly longer in patients receiving VYXEOS® (9.6 months) than those receiving traditional 7 + 3 cytarabine and daunorubicin (5.9 months).¹⁵

VYXEOS® is approved for adults with newly diagnosed AML that develops secondarily to other chemotherapeutic regimens (therapy-related AML, or t-AML) or AML with myelodysplasia-related changes (AML-MRC). It has a Boxed Warning for dosing errors, due to dosing that differs from daunorubicin or cytarabine administered separately.¹⁵

Gemtuzumab ozogamicin (MYLOTARG™) for injection [approved in 2017]

CD33 is expressed in immature myeloblasts but not in either mature hematopoietic stem cells or nonhematopoietic cells, making it a prime target for therapy in AML.¹¹ Gemtuzumab ozogamicin is a humanized anti-CD33 antibody linked to N-acetyl gamma calicheamicin, a cytotoxic agent. It is internalized after binding to CD33-expressing cells and induces cell cycle arrest and cell death by apoptosis.^{11,16}

In 2000, gemtuzumab ozogamicin received FDA approval through an accelerated process as a monotherapy for older patients with r/r CD33-positive AML. It was voluntarily withdrawn from the market after subsequent data failed to show clinical benefit and revealed an increase in treatment-related mortality. FDA re-approval in 2017 was prompted by data from clinical studies using a different dosing regimen and a new patient population showing significant clinical benefit in.^{11,16}

- Adults with newly diagnosed, CD33-positive AML as a single agent or in combination with 7 + 3
- Adults and children (>2 years) with r/r CD33-positive AML as a single agent


In a meta-analysis of 5 clinical trials, 5-year OS of all patients who received gemtuzumab ozogamicin with standard 7 + 3 induction chemotherapy as frontline therapy was 34.6%, compared to 30.7% in those that received standard chemotherapy alone. When restricted to just those patients with favorable risk, OS was 77.5% in those patients receiving gemtuzumab ozogamicin and 55% in those receiving standard induction chemotherapy alone.²⁶ Gemtuzumab ozogamicin has a Boxed Warning for hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD).

FMS-like Tyrosine Kinase 3 (FLT3) Inhibitors

FLT3 is a tyrosine kinase receptor expressed on myeloid and lymphoid progenitor cells. Upon binding its ligand, the receptor dimerizes and activates downstream signaling pathways mediating differentiation and growth²⁴ (**Figure 1**). Mutations in FLT3-ITD occur in ~30% of all AML cases, resulting in the activation of tyrosine kinase activity, signaling and proliferation.²⁶

Figure 1. FLT3 mutations in AML

Simplified schematic of the FLT3 receptor dimerizes, autophosphorylates, and activates downstream signaling pathways resulting in the proliferation of myeloid progenitor cells and an inhibition of differentiation. Gain-of-function mutations in the juxtamembrane region (FLT3-ITD) and in the tyrosine kinase domains (FLT3-TKD) resulting in ligand-independent FLT3 receptor activation are common driver mutations in AML.



ITD: internal tandem duplication; TKD: tyrosine kinase domain

Internal tandem duplication (ITD) mutations (FLT3-ITD) (**Figure 1**) are common driver mutations in AML, accounting for ~25% of all cases. Patients with FLT3-ITD mutations typically present with high leukemic burden and have a higher risk of relapse and shorter OS.^{26,27} Another 10% of AML patients carry mutations in the tyrosine kinase domain of FLT3 (FLT3-TKD), but the prognostic value of these mutations is not clear. It's also been shown that mutations can evolve from diagnosis to relapse, suggesting mutation testing may be necessary at multiple timepoints.²⁶

Multiple small molecules targeting FLT3 have been developed, and to date 3 have received FDA approval for the treatment of FLT3-mutated AML: midostaurin, gilteritinib and quizartinib.

Midostaurin (RYDAPT®) capsules [approved in 2017]

Midostaurin inhibits signaling by wild-type FLT3, *FLT3*-ITD and *FLT3*-TKD, in addition to other kinases. Disruption of FLT3 signaling by midostaurin inhibits proliferation and induces apoptosis in leukemic cells harboring ITD and TKD mutant FLT3, in addition to cells that overexpress wild-type FLT3.^{17,27}

In a phase 3 trial, 717 patients with newly diagnosed *FLT3*-mutated AML were stratified by *FLT3* mutational status and randomized 1:1 to receive midostaurin or placebo in combination with standard 7 + 3 induction and consolidation chemotherapy, followed by maintenance with midostaurin or placebo for up to 1 year.

Midostaurin plus standard 7 + 3 chemotherapy was found to be superior to placebo plus standard chemotherapy — 4-year OS in the midostaurin arm was 51% compared to 44% in the control arm.²⁷

Midostaurin capsules are indicated for *FLT3*-positive (both ITD and TKD mutated) newly diagnosed AML as detected by an [FDA-approved test](https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools) (www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools) in combination with standard 7 + 3 cytarabine and daunorubicin induction and cytarabine consolidation.¹⁷

Gilteritinib (XOSPATA®) oral tablets [approved in 2018]

Gilteritinib is a second-generation FLT3 inhibitor with more FLT3 specificity and less off-target activity against other kinases than midostaurin.²⁸ It inhibits wild-type FLT3 in addition to *FLT3*-ITD and *FLT3*-TKD.¹⁸ Gilteritinib was approved as a single agent for adults with r/r AML with *FLT3* mutations as detected by an [FDA-approved test](https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools).

In the phase 3 trial, 371 adults with r/r AML with a *FLT3* mutation were randomized 2:1 to receive either 120 mg gilteritinib daily over continuous 28-day cycles or salvage chemotherapy (either intensive or low-intensity regimen). In the final analysis, 14.2% of patients in the gilteritinib arm achieved CR vs 10.5% in the chemotherapy arm. Patients receiving gilteritinib survived significantly longer than those assigned to the chemotherapy arm (median 9.3 months vs 5.6 months).¹⁸

Gilteritinib has a Boxed Warning for differentiation syndrome, which occurred in 11 of 319 patients treated with gilteritinib in clinical trials.¹⁸

Quizartinib (VANFLYTA®) tablets [approved in 2023]

Quizartinib is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is *FLT3* internal tandem duplication (ITD)-positive as detected by an [FDA-approved test](https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools).⁵³

Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with *FLT3*-ITD-positive newly diagnosed AML.⁵³ The efficacy of quizartinib in combination with chemotherapy was evaluated in QuANTUM-First (NCT02668653), a randomized, double-blind, placebo-controlled study of 539 patients with newly diagnosed *FLT3*-ITD positive AML. Patients were stratified by age (<60 versus ≥60 years), white blood cell count at diagnosis (<40x10⁹/L versus ≥40x10⁹/L), and region (North America, Europe versus Asia, other regions). Patients were randomized (1:1) to receive quizartinib (n=268) or placebo (n=271) in combination with induction and consolidation therapy and as maintenance monotherapy. There was no re-randomization at the start of post consolidation therapy. Patients who proceeded to hematopoietic stem cell transplantation (HSCT) initiated maintenance therapy after recovery from the HSCT. Efficacy was established on the basis of overall survival (OS), measured from the date of randomization until death by any cause. The primary analysis was conducted after a minimum follow-up of 24 months after the randomization of the last patient. The study demonstrated a statistically significant improvement in OS for the quizartinib arm.⁵³

Quizartinib is available only through a restricted distribution program under a REMS called the VANFLYTA REMS because of the serious risk of QT prolongation, torsades de pointes, and cardiac arrest. Monitoring electrocardiograms and levels of serum electrolytes is required. Quizartinib should be reduced, interrupted, or permanently discontinued as appropriate. The most common (>20%) adverse reactions, including laboratory abnormalities, are lymphocytes decreased, potassium decreased, albumin decreased, phosphorus decreased, alkaline phosphatase increased, magnesium decreased, febrile neutropenia, diarrhea, mucositis, nausea, calcium decreased, abdominal pain, sepsis, neutropenia, headache, creatine phosphokinase increased, vomiting, and upper respiratory tract infection.⁵³

Isocitrate Dehydrogenase (IDH) Inhibitors

The IDH enzymes comprise 3 enzymes (*IDH1*, *IDH2* and *IDH3*) involved in the citric acid cycle—the central driver of cellular respiration—converting isocitrate to α -ketoglutarate. Gain-of-function mutations in *IDH1* and *IDH2* generate excess 2-hydroxyglutarate (2-HG) instead of α -ketoglutarate, which is likely an early, critical contributor to oncogenesis due to its disruption of metabolic and epigenetic mechanisms involved in cellular differentiation.^{12,29,30}

IDH1 and *IDH2* mutations have been implicated in several malignancies, including glioma, cholangiocarcinoma, chondrosarcoma, myelodysplastic syndromes and AML. In fact, nearly 20% of AML cases are *IDH*-mutant, with *IDH2*-mutations being more prevalent than *IDH1*. Characteristics associated with *IDH*-mutant AML include increased patient age and intermediate risk cytogenetics.^{12,30}

In vitro studies have established that inhibiting mutant *IDH* in leukemic cells reduces 2-HG production, reverses epigenetic changes and releases the myeloid differentiation block.²⁹ Multiple small molecule inhibitors of mutant *IDH* are in development, and 2 have been approved by the FDA for the treatment of adults with AML with demonstrated *IDH* mutations. Both products are approved for r/r AML, and one is approved for newly diagnosed patients ≥ 75 years or who have comorbidities that preclude use of intensive induction chemotherapy.

Enasidenib (IDHIFA®) oral tablets [approved in 2017]

In vitro studies reveal enasidenib selectively inhibits mutant *IDH2* variants R140Q, R172S and R172K at 40-fold lower concentrations than wild type IDH. Enasidenib was approved in 2017 for the treatment of adults with r/r AML with an *IDH2* mutation as identified by an [FDA-approved test](#).¹⁹

In a single-arm trial, 199 adults with r/r AML were given enasidenib daily until disease progression or unacceptable toxicity. Efficacy was determined based on CR + CR with hematologic improvement (CRh) percentage, duration of response, and the rate of conversion from transfusion dependence to transfusion independence. After a median follow-up of 6.6 months, 23% of patients achieved CR/CRh with a median duration of response of 8.2 months. Of 157 patients dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 34% became independent of these transfusions during any 56-day post-baseline period.¹⁹

Enasidenib has a Boxed Warning for differentiation syndrome, which occurred in 14% of patients in clinical trials.¹⁹ In November 2018, the FDA released a Safety Announcement warning that signs and symptoms of differentiation syndrome are not being recognized in patients receiving enasidenib and encouraged healthcare professionals to be alert for initial symptoms, which can be difficult to distinguish from cardiogenic pulmonary edema, pneumonia or sepsis.³¹

Ivosidenib (TIBSOVO®) oral tablets [approved in 2018]

Ivosidenib is a potent inhibitor of the mutant *IDH1* enzyme (the most common mutations leading to increased levels of 2-HG are R132H and R132C). In vitro studies show that ivosidenib inhibits these mutations at much lower concentrations than wild type *IDH1*. Ivosidenib is approved for treatment of adults with AML and *IDH1* mutation as identified by an [FDA-approved test](#).²⁰ Ivosidenib as monotherapy or in combination with azacitidine is indicated for patients with newly diagnosed AML who are at least 75 years and older or who have comorbidities that preclude use of intensive induction chemotherapy. Ivosidenib is indicated as monotherapy for adults with r/r AML.

Ivosidenib was studied in a single-arm trial of 28 adults with newly diagnosed AML with an *IDH1* mutation. Subjects were over 75 years of age or had comorbidities that precluded the use of intensive induction chemotherapy. They received 500 mg ivosidenib daily until disease progression, unacceptable toxicity, or stem cell transplant (2 patients proceeded to transplant). After a median followup of 8.1 months, 42.9% achieved CR/CRh (the median duration of response could not be estimated). Of 17 patients dependent on RBC and/or platelet transfusion at baseline, 41.2% became independent of these transfusions during any 56-day post-baseline period.²⁰

The efficacy and safety of ivosidenib were also evaluated in a single arm trial in 174 adults with r/r AML, who were given 500 mg ivosidenib daily until disease progression, unacceptable toxicity, or stem cell transplant (12% proceeded to transplant). After a median follow-up of 6.6 months, 32.8% achieved CR/CRh with a median duration of response of 8.2 months. Of 110 patients dependent on RBC and/or platelet transfusion at baseline, 37.3% became independent of these transfusions during any 56-day post-baseline period.²⁰

The combination of ivosidenib plus azacitidine in patients with newly diagnosed AML was evaluated in the randomized, placebo-controlled, phase 3 AGILE study. The primary

endpoint of event-free survival, at a median followup of 12.4 months, favored ivosidenib plus azacitidine over placebo plus azacitidine (hazard ratio 0.33; 95% confidence interval, 0.16- 0.69; $P = 0.002$), with estimated probability of remaining event-free at 12 months of 37% for ivosidenib plus azacitidine-treated patients and 12% for placebo plus azacitidine. The estimated probability that a patient would remain event-free at 12 months was 37% in the ivosidenib-and-azacitidine group and 12% in the placebo-and-azacitidine group. Median OS was also superior in the ivosidenib group (24.0 months, versus 7.9 for the placebo group; $P = 0.001$). The most common grade 3 or higher adverse events of grade 3 or higher were febrile neutropenia and neutropenia, while differentiation syndrome (any grade) occurred in 14% of patients in the ivosidenib arm and 8% of patients in the placebo arm.³²

Like enasidenib, ivosidenib has a Boxed Warning for differentiation syndrome, which occurred in 25% of patients with newly diagnosed AML and 19% of those with r/r AML in clinical trials. The FDA Safety Announcement mentioned above warns healthcare providers to be alert for symptoms of differentiation syndrome in patients receiving ivosidenib as well as enasidenib.³¹

Olutasidenib (REZLIDHIA™) oral capsules **[approved in 2022]**

The latest in this class to be approved is olutasidenib, an *IDH1* inhibitor indicated for treatment of adults with r/r AML with a susceptible *IDH1* mutation as detected by an [FDA-approved test](#).²⁴

That approval was based on results from Study 2102-HEM-101, an open-label, single-arm, multicenter clinical trial including 147 adult patients with r/r AML with a confirmed *IDH1* mutation. In these patients, the rate of CR plus CR with partial hematologic recovery (CRh) was 35% (32% CR, 2.7% CRh) and median duration of CR+CRh was 25.9 months. About one-third of patients dependent on red blood cell or platelet transfusions became transfusion independent in the post-baseline period.³³

In other recent reports from this study, olutasidenib in combination with azacitidine was well tolerated and induced durable CR or CRh in patients with *IDH1*-mutated AML, and a subset of patients achieved transfusion independence.^{34,35}

Common adverse reactions with olutasidenib include nausea, fatigue or malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.³³ Similar to enasidenib and ivosidenib, prescribing information

for olutasidenib includes a Boxed Warning regarding the risk of differentiation syndrome, which can be fatal. Olutasidenib should be withheld if differentiation syndrome is suspected, and until symptoms resolve the patient should be treated with corticosteroids and undergo hemodynamic monitoring.²⁴

BCL-2 Inhibitor

Venetoclax tablets (VENCLEXTA®) **[approved in 2018]**

B-cell leukemia/lymphoma-2 (BCL-2) family members are proteins that bind and sequester pro-apoptotic proteins in cancer cells. It has been demonstrated that BCL-2 mediates chemoresistance and promotes survival of leukemic blast and progenitor cells,^{10,13,36} and BCL-2 overexpression is a common finding in hematologic malignancies.³⁷

Venetoclax is a potent and selective BCL-2 inhibitor that has been investigated in combination with other therapies in multiple hematologic malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, and AML. Scores of clinical trials are underway.³⁷

In 2018, venetoclax received approval for the front-line treatment of AML in combination with hypomethylating agents (azacitidine or decitabine) or low dose cytarabine in adults 75 years or older or who have comorbidities that preclude intensive induction chemotherapy. The indication was granted under accelerated approval based on the response rates; full approval was granted in 2020 based on data from confirmatory trials.²¹

Venetoclax was evaluated in a non-randomized phase 1b dose escalation and expansion trial in combination with azacitidine or decitabine in newly diagnosed AML in patients who were ineligible for intensive chemotherapy. With a median follow-up of 8.9 months, 67% of patients (all doses) achieved CR + CRi. The median duration of response was 11.3 months, and median OS was 17.5 months.³¹ In comparison, response rates for decitabine or azacitidine monotherapy in this population ranged from 20% to 40%.³⁶

Venetoclax in combination with LDAC was evaluated in a non-randomized, open-label phase 1b/2 study in older patients (≥ 60 years) with AML who were ineligible for intensive chemotherapy. CR + CRi was 54% with a median OS of 10.1 months. These rates compare favorably with LDAC monotherapy, with CR/CRi rates of 11%-19% and median OS of 5.5 months.¹³

Data that led to the approval come from the phase 3 VIALE-A and VIALE-C trials, which respectively evaluated the combinations of venetoclax plus azacitidine (versus placebo plus azacitidine) and venetoclax plus LDAC (versus placebo plus LDAC). Both studies included patients with newly diagnosed AML ineligible for intensive induction therapy. In VIALE-A, OS in the venetoclax plus azacitidine arm was 14.7 months versus 9.6 months for placebo plus azacitidine, while median CR duration was 18 months versus

13.4 months for venetoclax plus azacitidine and placebo plus azacitidine, respectively. In VIALE-C, the primary endpoint of OS was not met, though the study was smaller than VIALE-A, and the median CR rate was 27% with a median duration of 11.1 months for venetoclax plus LDAC versus 7.4% and 8.3 months for placebo plus LDAC. Serious adverse events in VIALE-A included febrile neutropenia, pneumonia, sepsis, and hemorrhage, while in VIALE-C they included pneumonia, febrile neutropenia, and sepsis.³⁸


Hedgehog Pathway Inhibitor

Glasdegib (DAURISMO™) tablets [approved in 2018]

The hedgehog (Hh) pathway is a signaling pathway that plays a key role in embryonic development of vertebrates. It is controlled by two cellular membrane receptors, Patch (PTCH) and Smoothened (SMO). SMO transmits activating signals to downstream components (**Figure 2**), and PTCH normally functions to inhibit signaling by SMO when not bound to its ligand. When the hedgehog ligand binds to PTCH, PTCH is internalized and degraded, allowing SMO to activate downstream effectors. Abnormal activation of Hh pathway signaling has been identified in several leukemias and leukemia stem cells.³⁹

Figure 2. The Hedgehog Pathway

The Hh pathway is controlled by Patch (PTCH) and Smoothened (SMO), two transmembrane receptors. **OFF:** When PTCH is not bound to its ligand, it functions to inhibit signaling by SMO. **ON:** When Hh is bound, PTCH is internalized and degraded, allowing SMO to accumulate and signal downstream effectors, including inducing gene expression.



Glasdegib is an orally bioavailable small molecule that binds to and inhibits signaling by SMO. It gained FDA approval in 2018 in combination with LDAC for the treatment of newly diagnosed AML in adults 75 years and older, or who have comorbidities that preclude use of intensive induction chemotherapy.²²

The efficacy of glasdegib was evaluated in a randomized, open-label study of 132 patients with newly diagnosed AML or highrisk MDS not eligible for intensive chemotherapy. The trial compared glasdegib with LDAC vs LDAC alone. Median OS was 8.8 months for glasdegib + LDAC, vs 4.9 months for LDAC alone. The CR rate was 18.2% in the glasdegib + LDAC arm vs 2.6% for LDAC alone.²¹

Glasdegib has a Boxed Warning for embryo-fetal toxicity.²²

Hypomethylating Agent (HMA)

Azacitidine (ONUREG™) oral tablets [approved 2020]

Azacitidine (ONUREG™, CC-486) oral tablets are approved for continued treatment of adult patients with AML who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative treatment.²³ This treatment, a pyrimidine nucleoside analog of cytidine, is an inhibitor of DNA and RNA methyltransferases.⁴⁰

The pharmacokinetics of this oral hypomethylating agent are different from those of injectable azacitidine, which has a plasma half-life that is short.⁴¹ By contrast, oral azacitidine can be given in extended dosing schedules to provide sustained therapeutic activity.⁴²

The approval of oral azacitidine was based in part on data from QUAZAR, a phase 3 randomized, placebo-controlled trial including 472 patients (median age, 68 years) with AML that was in first remission following intensive chemotherapy. Maintenance therapy with oral azacitidine provided longer OS (the primary endpoint of the study) and relapse-free survival versus placebo. The median OS was 24.7 months for oral azacitidine versus 14.8 months for placebo ($P < 0.001$), and efficacy benefits were consistent across subgroups such as age, sex, WHO AML classification, and cytogenetic risk at the time of induction.⁴³

In QUAZAR, adverse events were primarily hematologic and gastrointestinal. The most frequently observed grade 3–4 adverse events in patients receiving oral azacitidine were neutropenia in 41% (and 24% for placebo) and thrombocytopenia in 22% (and 21% for placebo).⁴³ The prescribing information for oral azacitidine indicates that it should not be substituted for intravenous or subcutaneous azacitidine, as the indications and dosing regimens differ between these formulations.²³

Menin Inhibitor

Revumenib (REVUFORJ®) tablets [approved in 2024]

KMT2A leads to oncogenic fusion proteins that upregulate leukemogenic homeobox (HOX) genes and their DNA-binding cofactor Meis homeobox 1 (MEIS1).^{47,48} The protein menin is a crucial mediator of the pathogenesis of *KMT2A* leukemia. Menin is essential for binding of the

KMT2A protein complex to the HOX gene promoter.⁴⁹ In preclinical models, disruption of the menin-*KMT2A* interaction reverses this aberrant gene expression, leading to hematopoietic differentiation and an antileukemic effect.^{50, 51}

Revumenib is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (*KMT2A*) translocation in adult and pediatric patients 1 year and older.

The efficacy of revumenib was evaluated in a single-arm cohort of an open-label, multicenter trial (SNDX-5613-0700, NCT04065399; AUGMENT-101) in adult and pediatric patients at least 30 days old with relapsed or refractory (R/R) acute leukemia with a *KMT2A* translocation. Patients with an 11q23 partial tandem duplication were excluded. Eligibility required a QTcF < 450 msec at study baseline. Treatment consisted of revumenib at a dose approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor until disease progression, unacceptable toxicity, failure to achieve morphological leukemia-free state by 4 cycles of treatment, or hematopoietic stem cell transplantation (HSCT). Efficacy was established based on the rate of complete remission (CR) plus CR with partial hematologic recovery (CRh), the duration of CR+CRh, and the rate of conversion from transfusion dependence to transfusion independence. The median follow-up was 5.73 months (range, 0.3 to 28.9 months). On subgroup analysis, CR+CRh was achieved by 18/86 (21%) of patients with AML, 3/16 (19%) of patients with ALL, and 1/2 (50%) of patients with MPAL.⁵²

The most common adverse reactions ($\geq 20\%$) were hemorrhage, nausea, increased phosphate, musculoskeletal pain, infection, increased aspartate aminotransferase, febrile neutropenia, increased alanine aminotransferase, increased intact parathyroid hormone, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, decreased phosphate, increased triglycerides, decreased potassium, decreased appetite, constipation, edema, viral infection, fatigue, and increased alkaline phosphatase.⁵⁴ A warning box regarding the risk of differentiation syndrome, which can be fatal is noted. If differentiation syndrome is suspected revumenib should be held and the patient should be treated with corticosteroids and undergo hemodynamic monitoring. Revumenib can be restarted once symptoms have resolved.⁵²

Recommendations

For any patient with AML, NCCN Guidelines strongly encourage enrollment in a clinical trial. For patients not enrolled in a trial, cytogenetics and risk stratification guide treatment decisions.² NCCN Guidelines are available at www.NCCN.org, provide specific treatment recommendations for induction therapy through to r/r disease.² In addition, the updated 2022 ELN expert panel recommendations include specific guidance on systemic therapy for AML, HSCT, and clinical trials.⁷


Beat AML® Master Trial

The Leukemia & Lymphoma Society's (LLS's) Beat AML® Master Trial is a groundbreaking study designed to facilitate the approval of new drugs and optimize the treatment for AML by developing individualized treatment approaches. The protocol is designed to facilitate a collaborative and responsive consortium that can serve as a model for future cancer clinical trials.

The trial is a collaboration between LLS (the trial sponsor), academic researchers, pharmaceutical companies, a genomic provider, and a clinical research organization. It is open to patients 60 years and older with newly diagnosed AML and patients with R/R AML, regardless of age.

Upon diagnosis, enrolled patients receive a genomic screen via bone marrow biopsy. Based on the results of the screen, each patient is assigned a personalized therapy on one of several sub-studies. Sites and arms of the trial are expected to increase as data accumulate with the potential to test novel drug combinations (**Figure 3**). The trial is currently enrolling patients at 16 cancer centers across the United States. More information, including how to enroll patients, can be found at <https://www.LLS.org/bringing-precision-medicine-aml-patients>.

Figure 3. The Beat AML® Master Trial



LLS Clinical Trial Nurse Navigators are registered nurses with expertise in blood cancers. They are available to provide individualized clinical trial searches. Information about the LLS Clinical Trial Support Center can be found at <https://www.LLS.org/navigation>. Additional resources are listed below.

This publication is designed to provide accurate and authoritative information about the subject matter covered.

It is distributed as a public service by The Leukemia & Lymphoma Society (LLS), with the understanding that LLS is not engaged in rendering medical or other professional services.

Acknowledgements

LLS gratefully acknowledges

Alice S. Mims, MD, MSCR

Acute Leukemia Research Section Head
Associate Division Director Clinical Research
Professor of Medicine
The Ohio State University Comprehensive Cancer Center

For her review of *Facts About Acute Myeloid Leukemia* and her important contributions to the material presented in this publication.

We're Here to Help

LLS is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS has regions throughout the United States and Canada. To find the region nearest to you, visit our website at www.LLS.org/ChapterFind or contact

The Leukemia & Lymphoma Society

1201 15th Street N.W., Suite 410,
Washington, D.C. 20005
Phone Number: (800) 955-4572
(M-F, 9 a.m. to 9 p.m. ET)
Website: www.LLS.org

LLS offers free information and services for patients and families touched by blood cancers as well as for healthcare professionals. The resources listed below are available to you and your patients and are meant to be a complement to the HCP team and an additional source of support.

Consult with an Information Specialist. Information Specialists are highly trained social workers and nurses who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information. Language services are available. For more information, please:

- Call: (800) 955-4572 (M-F, 9 a.m. to 9 p.m. ET)
- Visit: www.LLS.org/IRC
- Email or Live chat: www.LLS.org/InformationSpecialists

Clinical Trials Support Center (CTSC). Work one-on-one with an LLS clinical trial nurse navigator who will personally assist throughout the entire clinical trial process. A nurse navigator will help identify potential clinical trials and overcome the barriers to enrollment (navigators help

HCPs and patients). For more information about this free service, please:

- Call an Information Specialist: (800) 955-4572 to be referred to the CTSC
- Visit: www.LLS.org/CTSC
- Complete a referral form for your patient at: www.LLS.org/CTSCreferral

Nutrition Consultations. Nutrition Education Services Center (NESC) provides one-on-one *free* nutrition education and consultations to patients and caregivers of all cancer types with registered dietitians who have expertise in oncology nutrition.

- Visit: www.LLSnutrition.org

Free Information Booklets. LLS offers free education and support publications that can either be read online or downloaded. Free print versions can be ordered. For more information, please:

- Visit: www.LLS.org/booklets

Información en Español. (LLS information in Spanish) Para mayor información por favor:

- Visite: www.LLS.org/espanol

LLS Community. LLS Community is an online social network and registry for patients, caregivers, and healthcare professionals. It is a place to ask questions, get informed, share your experience, and connect with others. To join:

- Visit: www.LLS.org/community

LLS Regions. LLS offers community support and services in the United States and Canada including the *Patti Robinson Kaufmann First Connection Program* (a peer-to-peer support program), in-person support groups, and other great resources. For more information about these programs or to contact your region, please:

- Call: (800) 955-4572
- Visit: www.LLS.org/ChapterFind

Patti Robinson Kaufmann First Connection® Program. A free peer-to-peer support program that connects patients and their loved ones to a trained peer volunteer who has gone through a similar experience.

- www.LLS.org/FirstConnection

Acute Myeloid Leukemia Resource:

- www.LLS.org/Leukemia

Resources for Healthcare Professionals: Webinars, Podcasts, In-person Education Programs, Videos, and Fact Sheets:

- www.LLS.org/CE (free accreditation)
- www.LLS.org/HCPpodcast
- www.LLS.org/HCPvideos
- www.LLS.org/HCPbooklets

Resources for your Patients:

- www.LLS.org/programs
- www.LLS.org/EducationVideos
- www.LLS.org/podcast
- www.LLS.org/PatientSupport

Additional Resources

The National Cancer Institute (NCI)

www.cancer.gov

(800) 422-6237

The National Cancer Institute, part of the National Institutes of Health, is a national resource center for information and education about all forms of cancer. The NCI also provides a clinical trial search feature, the PDQ® Cancer Clinical Trials Registry, at www.cancer.gov/clinicaltrials, where healthcare professionals and patients can look for clinical trials.

References

1. Siegel RL, Miller KD, Wagle NS, Jemal A. *CA Cancer J Clin.* 2023;73:17-48.
2. National Comprehensive Cancer Network. NCCN Guidelines – Acute Myeloid Leukemia. Version 2.2025, January 7, 2025. www.NCCN.org. Accessed May 27th, 2025.
3. National Cancer Institute. <https://seer.cancer.gov/statistics-network/explorer/application.html>. Accessed May 1, 2023.
4. Shallis RM, Wang R, Davidoff A, et al. *Blood Rev.* 2019;36:70-87.
5. Estey EH. *Am J Hematol.* 2018;93:1267-1291.
6. Arber DA, Orazi A, Hasserjian R, et al. *Blood.* 2016;127(20):2391-2405.
7. Döhner H, Wei AH, Appelbaum FR, et al. *Blood.* 2022;140:1345-1377.
8. Medeiros BC, Chan SM, Daver NG, et al. *Am J Hematol.* 2019;94:803-11.
9. Khoury JD, Solary E, Abla O, et al. *Leukemia.* 2022;36:1703-1719.
10. Knight T, Edwards H, Taub JW, Ge Y. *Cancer Manag Res.* 2019;11:3197-3213.
11. Selby C, Yacko LR, Glode AE. *J Adv Pract Oncol.* 2019;10:68-82.
12. Galkin M, Jonas BA. *Core Evid.* 2019;14:3-17.
13. Wei AH, Strickland SA, Hou J-Z, et al. *J Clin Oncol.* 2019;37:1277-84.
14. Ferrara F, Lessi F, Vitagliano O, et al. *Cancers.* 2019;224; doi:10.3390/cancers11020224.
15. VYXEOS® [Prescribing Information]. Palo Alto, CA. Jazz Pharmaceuticals, Inc. 2022.
16. MYLOTARG™ [Prescribing Information]. Philadelphia, PA. Wyeth Pharmaceuticals Inc. 2021.
17. RYDAPT® [Prescribing Information]. East Hanover, NJ. Novartis Pharmaceuticals Corporation. 2021.
18. XOSPATA® [Prescribing Information]. Northbrook, IL. Astellas Pharma US, Inc. 2021.
19. IDHIFA® [Prescribing Information]. Princeton, NJ. Bristol Myers Squibb Company. 2022.
20. TIBSOVO® [Prescribing Information]. Boston, MA. Servier Pharmaceuticals LLC. 2022.
21. VENCLEXTA® [Prescribing Information]. North Chicago, IL. AbbVie Inc. 2022.
22. DAURISMO™ [Prescribing Information]. New York, NY. Pfizer Inc. 2023.
23. ONUREG™ [Prescribing Information]. Princeton, NJ. Bristol-Myers Squibb Company. 2022.
24. REZLIDHIA™ [Prescribing Information]. South San Francisco, CA. Rigel Pharmaceuticals, Inc. 2022.
25. Mayer LD, Tardi P, Louie AC. *Int J Nanomed.* 2019;14:3819-3830.
26. Daver N, Schlenk RF, Russell NH, Levis MJ. *Leukemia.* 2019;33:299-312.
27. Yilmaz M, Daver N. *Drugs.* 2019;79:1177-86.
28. Short N, Kantarjian H, Ravandi F, Daver N. *Ther Adv Hematol.* 2019;10:1-18.
29. Nassereddine S, Lap CJ, Tabbara IA. *OncoTargets Ther.* 2019;1212;303-8.
30. Golub D, Iyengar N, Dogra S, et al. *Front Oncol.* 9:417.
31. Enasidenib Drug Safety Communication. US Food and Drug Administration. <https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-warns-symptoms-serious-condition-affecting-blood-cells-are-not-being-recognized-leukemia>. Accessed May 1, 2023.
32. Montesinos P, Recher C, Vives S, et al. *N Engl J Med.* 2022;386(16):1519-1531.
33. Food and Drug Administration (FDA). Content current as of December 1, 2022. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation>. Accessed May 2, 2023.
34. Watts JM, Baer MR, Yang J, et al. *Lancet Haematol.* 2023;10(1):e46-e58.
35. Cortes JE, Esteve J, Bajel A, et al. *Blood.* 2021; 138 (Supplement 1): 698.
36. DiNardo CD, Pratz K, Pullarkat V, et al. *Blood.* 2019;133:7-17.
37. Perini GF, Ribeiro GN, Neto JVP, et al. *J Hematol Oncol.* 2019;11:65.
38. ASH Clinical News. October 16, 2022. <https://ashpublications.org/ashclinicalnews/news/5338/Venetoclax-Combination-Granted-Full-Approval-for>. Accessed May 2, 2023.
39. Savona MR, Pollyea DA, Stock W, et al. *Clin Cancer Res.* 2018;24:2294-2303.
40. Jen EY, Wang X, Li M, et al. *Clin Cancer Res.* 2022;28:2989-2993.
41. Garcia-Manero G, Gore SD, Cogle C, et al. *J Clin Oncol.* 2011;29:2521-2527.
42. Laille E, Shi T, Garcia-Manero G, et al. *PLoS One.* 2015;10:e0135520.
43. Wei AH, Döhner H, Pocock C, et al. *N Engl J Med.* 2020;383:2526-2537.
44. What's new in AML Classification (WHO 2022 vs International Consensus Classification) <https://www.cap.org/member-resources/articles/whats-new-in-aml-classification-who-2022-vs-international-consensus-classification>. College of American Pathologist. Accessed on May 27, 2025.
45. Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. *Am J Hematol.* 2025 May;100(5):860-891. doi: 10.1002/ajh.27625. Epub 2025 Feb 12. PMID: 39936576; PMCID: PMC11966364.
46. Döhner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. *Blood.* (2024)144(21):2169–2173. <https://doi.org/10.1182/blood.2024025409>.
47. Thorsteinsdottir U, Kroon E, Jerome L, et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. *Mol Cell Biol.* 2001;21:224–234. doi:10.1128/MCB.21.1.224-234.2001.
48. Yu BD, Hess JL, Horning SE, et al. Altered Hox expression and segmental identity in Mll-mutant mice. *Nature.* 1995;378:505–508. doi:10.1038/378505a0.
49. Yokoyama A, Somervaille TC, Smith KS, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. *Cell.* 2005;123:207–218. doi:10.1016/j.cell.2005.09.025.
50. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. *Nat Chem Biol.* 2012;8:277–284. doi:10.1038/nchembio.773.
51. Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. *Cancer Cell.* 2019;36:660–673.e11. doi:10.1016/j.ccell.2019.11.001.
52. REVUFORJ® [Prescribing Information] New York, NY. Syndax Pharmaceuticals, Inc. 2025.
53. VANFLYTA® [Prescribing Information]. Basking Ridge, NJ. Daiichi Sankyo, Inc. 2023.
54. Food and Drug Administration (FDA). FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation>. Accessed on June 5th, 2025